Secondary hematologic malignancies with poly adenosine diphosphate ribose polymerase inhibitors: Is the buzz real? -Insights from a meta-analysis of phase 3 randomized controlled trials

J Geriatr Oncol. 2019 May;10(3):518-520. doi: 10.1016/j.jgo.2019.01.008. Epub 2019 Jan 18.

Authors

Somedeb Ball¹, Anita Sultan², Myo H Zaw³, Kyaw Z Thein²

Affiliations

¹ Department of Internal Medicine, Texas Tech University Health Sciences Center, Lubbock, TX, USA. Electronic address: somedeb.ball@ttuhsc.edu.
² Division of Hematology and Oncology, Texas Tech University Health Sciences Center, Lubbock, TX, USA.
³ Department of Internal Medicine, University of Iowa, Iowa City, Iowa, USA.

PMID: 30665875
DOI: 10.1016/j.jgo.2019.01.008

No abstract available

Keywords: Acute myeloid leukemia; Meta-analysis; Niraparib; Ovarian neoplasms; PARP inhibitors; Rucaparib.

Publication types

Letter
Meta-Analysis
Systematic Review

MeSH terms

Aged
Clinical Trials, Phase III as Topic
Female
Hematologic Neoplasms / chemically induced*
Humans
Ovarian Neoplasms / drug therapy*
Poly Adenosine Diphosphate Ribose / adverse effects*
Poly Adenosine Diphosphate Ribose / antagonists & inhibitors
Randomized Controlled Trials as Topic

Substances

Poly Adenosine Diphosphate Ribose